全球骨髓增生性疾病藥物/治療市場研究報告 - 產業分析、規模、佔有率、成長、趨勢及預測（2025 年至 2033 年）

全球骨髓增生性疾病藥物/治療市場預計將經歷顯著擴張，預計 2025 年至 2033 年的年複合成長率(CAGR) 為 3.48%。根據市場分析，預計到 2033 年底市場規模將達到 138.2 億美元，高於 2024 年的 101.6 億美元。

全球骨髓增生性疾病 (MPD) 藥物及治療市場預計將在診斷率不斷提高和標靶治療技術進步的推動下實現成長。 JAK 抑制劑和干擾素製劑等新型藥物正在改善疾病管理和患者預後。未來的發展將側重於聯合療法、個人化醫療方法以及用於早期檢測和治療監測的新型生物標記。

此外，臨床試驗和法規核准的不斷增加正在加速創新療法的市場化。患者權益倡導和認知項目的興起正在提高診斷率和依從性。基因組分析和數位健康工具的進步正在促進精準醫療的發展。隨著血液腫瘤學的發展，MPD藥物和治療市場將繼續創新，提供有效、客製化且更安全的治療方案。

目錄

第1章：前言

• 報告描述
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法
  • 市場研究流程
  • 市場研究方法

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：骨髓增生性疾病藥物/治療 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業趨勢
• 波特五力分析
• 市場吸引力分析
  • 依疾病類型分析市場吸引力
  • 按藥品類別分析市場吸引力
  • 按給藥途徑進行的市場吸引力分析
  • 按最終用途進行的市場吸引力分析
  • 市場吸引力分析：按地區

第4章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料製造商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第5章：全球骨髓增生性疾病藥物/治療市場分析：依疾病類型

• 依疾病類型概述
• 依疾病類型分析歷史和預測數據
• 費城染色體陽性（Ph+）慢性骨髓性白血病
• 費城染色體陰性（Ph-）MPN
• 真性紅血球增多症
• 原發性血小板增多症
• 骨髓纖維化
• 其他疾病類型

第6章：全球骨髓增生性疾病藥物/治療市場分析：依藥物類別

• 按藥物類別概述
• 按藥物類別進行的歷史和預測數據分析
• 酪胺酸激酶抑制劑
• Janus激酶抑制劑
• 羥基脲
• 其他藥物類別

第7章：全球骨髓增生性疾病藥物/治療市場分析：依給藥途徑

• 依給藥途徑概述
• 按給藥途徑進行的歷史和預測數據分析
• 口服
• 注射劑

第 8 章：全球骨髓增生性疾病藥物/治療市場分析：依最終用途

• 按最終用途概述
• 按最終用途進行的歷史和預測數據分析
• 醫院
• 專科診所
• 其他最終用戶

第9章：全球骨髓增生性疾病藥物/治療市場分析：按地區

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美各細分市場銷售分析
  • 北美各國銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲各細分市場銷售分析
  • 歐洲各國銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區分部銷售分析
  • 亞太地區國家銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲各細分市場銷售分析
  • 拉丁美洲各國銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲分部銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東和非洲其他地區銷售分析

第 10 章：骨髓增生性疾病藥物/治療公司的競爭格局

• 骨髓增生性疾病藥物/治療市場競爭
• 夥伴關係/合作/協議
• 併購
• 新產品發布
• 其他發展

第 11 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• AbbVie Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Bristol-Myers Squibb Company
• 公司概況
• 公司收入
• 產品
• 最新動態
• Eli Lilly And Company
• 公司概況
• 公司收入
• 產品
• 最新動態
• GlaxoSmithKline Plc (GSK)
• 公司概況
• 公司收入
• 產品
• 最新動態
• GL Pharma GmbH Incyte Corporation
• 公司概況
• 公司收入
• 產品
• 最新動態
• Janssen Biotech Inc. (Johnson & Johnson)
• 公司概況
• 公司收入
• 產品
• 最新動態
• MorphoSys AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• Mylan NV (Viatris)
• 公司概況
• 公司收入
• 產品
• 最新動態
• Novartis Pharmaceuticals Corporation (Novartis AG)
• 公司概況
• 公司收入
• 產品
• 最新動態
• Takeda Pharmaceutical Company Limited
• 公司概況
• 公司收入
• 產品
• 最新動態
• Teva Pharmaceutical Industries Ltd
• 公司概況
• 公司收入
• 產品
• 最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，或者在私人公司的情況下可能不涵蓋

Global Myeloproliferative Disorders Drugs/Treatment Market is anticipated to experience remarkable expansion, with a projected Compound Annual Growth Rate (CAGR) of 3.48% from 2025 to 2033. According to the market analysis, the market size is forecasted to reach USD 13.82 Billion by the end of 2033, up from USD 10.16 Billion in 2024.

The global myeloproliferative disorders (MPD) drugs and treatment market is set for growth driven by increasing diagnosis rates and advancements in targeted therapies. Novel agents such as JAK inhibitors and interferon formulations are improving disease management and patient outcomes. Future developments will focus on combination therapies, personalized medicine approaches, and novel biomarkers for early detection and treatment monitoring.

Additionally, expanding clinical trials and regulatory approvals are accelerating market availability of innovative treatments. The rise of patient advocacy and awareness programs is enhancing diagnosis and adherence. Advances in genomic profiling and digital health tools are facilitating precision medicine. As hematologic oncology evolves, the MPD drugs and treatment market will continue to innovate, delivering effective, tailored, and safer therapeutic options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Myeloproliferative Disorders Drugs/Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disorder Type

• Philadelphia Chromosome-Positive (Ph+) CML
• Philadelphia Chromosome-Negative (Ph-) MPNs
• Polycythemia Vera
• Essential Thrombocythemia
• Myelofibrosis
• Other Disorder Types

By Drug Class

• Tyrosine Kinase Inhibitors
• Janus Kinase Inhibitors
• Hydroxyurea
• Other Drug Classes

By Route Of Administration

• Oral
• Injectable

By End-Use

• Hospitals
• Specialty Clinics
• Other End-Users
• List of Companies Profiled in the report
• AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc (GSK), GL Pharma GmbH Incyte Corporation, Janssen Biotech Inc. (Johnson & Johnson), MorphoSys AG, Mylan N.V. (Viatris), Novartis Pharmaceuticals Corporation (Novartis AG), Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Disorder Type
  • 3.7.2 Market Attractiveness Analysis By Drug Class
  • 3.7.3 Market Attractiveness Analysis By Route Of Administration
  • 3.7.4 Market Attractiveness Analysis By End-Use
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DISORDER TYPE

• 5.1. Overview By Disorder Type
• 5.2. Historical and Forecast Data Analysis By Disorder Type
• 5.3. Philadelphia Chromosome-Positive (Ph+) CML Historic and Forecast Sales By Regions
• 5.4. Philadelphia Chromosome-Negative (Ph-) MPNs Historic and Forecast Sales By Regions
• 5.5. Polycythemia Vera Historic and Forecast Sales By Regions
• 5.6. Essential Thrombocythemia Historic and Forecast Sales By Regions
• 5.7. Myelofibrosis Historic and Forecast Sales By Regions
• 5.8. Other Disorder Types Historic and Forecast Sales By Regions

6. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 6.1. Overview By Drug Class
• 6.2. Historical and Forecast Data Analysis By Drug Class
• 6.3. Tyrosine Kinase Inhibitors Historic and Forecast Sales By Regions
• 6.4. Janus Kinase Inhibitors Historic and Forecast Sales By Regions
• 6.5. Hydroxyurea Historic and Forecast Sales By Regions
• 6.6. Other Drug Classes Historic and Forecast Sales By Regions

7. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route Of Administration
• 7.2. Historical and Forecast Data Analysis By Route Of Administration
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Injectable Historic and Forecast Sales By Regions

8. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY END-USE

• 8.1. Overview By End-Use
• 8.2. Historical and Forecast Data Analysis By End-Use
• 8.3. Hospitals Historic and Forecast Sales By Regions
• 8.4. Specialty Clinics Historic and Forecast Sales By Regions
• 8.5. Other End-Users Historic and Forecast Sales By Regions

9. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT COMPANIES

• 10.1. Myeloproliferative Disorders Drugs/Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AbbVie Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Bristol-Myers Squibb Company
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Eli Lilly And Company
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. GlaxoSmithKline Plc (GSK)
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. GL Pharma GmbH Incyte Corporation
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Janssen Biotech Inc. (Johnson & Johnson)
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. MorphoSys AG
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Mylan N.V. (Viatris)
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Novartis Pharmaceuticals Corporation (Novartis AG)
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Takeda Pharmaceutical Company Limited
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Teva Pharmaceutical Industries Ltd
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Disorder Type (USD MN)
• Philadelphia Chromosome-Positive (Ph+) CML Market Sales By Geography (USD MN)
• Philadelphia Chromosome-Negative (Ph-) MPNs Market Sales By Geography (USD MN)
• Polycythemia Vera Market Sales By Geography (USD MN)
• Essential Thrombocythemia Market Sales By Geography (USD MN)
• Myelofibrosis Market Sales By Geography (USD MN)
• Other Disorder Types Market Sales By Geography (USD MN)
• Analysis By Drug Class (USD MN)
• Tyrosine Kinase Inhibitors Market Sales By Geography (USD MN)
• Janus Kinase Inhibitors Market Sales By Geography (USD MN)
• Hydroxyurea Market Sales By Geography (USD MN)
• Other Drug Classes Market Sales By Geography (USD MN)
• Analysis By Route Of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Injectable Market Sales By Geography (USD MN)
• Analysis By End-Use (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Specialty Clinics Market Sales By Geography (USD MN)
• Other End-Users Market Sales By Geography (USD MN)
• Global Myeloproliferative Disorders Drugs/Treatment Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Myeloproliferative Disorders Drugs/Treatment Report
• Market Research Process
• Market Research Methodology
• Global Myeloproliferative Disorders Drugs/Treatment Market Size, By Regions (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Disorder Type
• Market Attractiveness Analysis By Drug Class
• Market Attractiveness Analysis By Route Of Administration
• Market Attractiveness Analysis By End-Use
• Market Attractiveness Analysis By Regions
• Value Chain Analysis
• Global Market Analysis By Disorder Type (USD MN)
• Philadelphia Chromosome-Positive (Ph+) CML Market Sales By Geography (USD MN)
• Philadelphia Chromosome-Negative (Ph-) MPNs Market Sales By Geography (USD MN)
• Polycythemia Vera Market Sales By Geography (USD MN)
• Essential Thrombocythemia Market Sales By Geography (USD MN)
• Myelofibrosis Market Sales By Geography (USD MN)
• Other Disorder Types Market Sales By Geography (USD MN)
• Global Market Analysis By Drug Class (USD MN)
• Tyrosine Kinase Inhibitors Market Sales By Geography (USD MN)
• Janus Kinase Inhibitors Market Sales By Geography (USD MN)
• Hydroxyurea Market Sales By Geography (USD MN)
• Other Drug Classes Market Sales By Geography (USD MN)
• Global Market Analysis By Route Of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Injectable Market Sales By Geography (USD MN)
• Global Market Analysis By End-Use (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Specialty Clinics Market Sales By Geography (USD MN)
• Other End-Users Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.